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Using an electrochemiluminescence immunoassay, CYFRA 21-1 concentrations were measured in sera from 187 patients with
primary liver cancer (164 with hepatocellular carcinoma (HCC) and 23 with intrahepatic cholangiocarcinoma (ICC)) and 87 patients
with benign liver diseases. Concentrations of CYFRA 21-1 were significantly higher in patients with ICC (5.0; interquartile range 3.1–
10.7ngml
 1) than in those with benign liver disease (1.4; 1.0–1.9; Mann–Whitney U-test, Po0.0001) or HCC (1.7; 1.1–2.7; Mann–
Whitney U-test, Po0.0001). Using cutoff values selected for 95% specificity in the benign group (3.0ngml
 1), CYFRA 21-1 showed
higher sensitivity for ICC (87.0%) than three commonly used markers including a-fetoprotein (17.4%), carcinoembryonic antigen
(34.8%), and carbohydrate antigen 19-9 (60.9%). Serum CYFRA 21-1 increased in ICC from stages I/II to IV (Kruskal–Wallis test,
P¼0.0102). CYFRA 21-1 concentration increased with extent of local invasion, but not nodal status. Serum CYFRA 21-1 represents
a useful diagnostic test for ICC that offers high sensitivity. CYFRA 21-1 reflected differences in tumour burden, suggesting applicability
to staging and follow-up.
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Hepatocellular carcinoma (HCC), one of the most common
primary malignant tumours worldwide, is a leading cause of death
(Pisani et al, 1999). Since chronic infection with hepatitis B or C
virus (HBV or HCV) is closely related to development of HCC
(Ikeda et al, 1993; Nishiguchi et al, 1995; Takano et al, 1995), close
follow-up of patients with HBV or HCV infection has been
recommended to improve early HCC detection and maximise
opportunity for successful treatment (Liaw et al, 1986; Curley et al,
1995; Trevisani et al, 2002). While various imaging modalities can
be applied to diagnosis of primary liver cancer, the main
diagnostic test remains measurement of a-fetoprotein (AFP), the
best accepted serum tumour marker for HCC, in addition to
imaging (Oka et al, 1994; Curley et al, 1995; Trevisani et al, 2002).
Recent studies reported an increased risk of developing
intrahepatic cholangiocarcinoma (ICC) in patients with cirrhosis,
as is true for HCC (Sorensen et al, 1998; Kobayashi et al, 2000). In
Japan and east Asia, chronic HCV infection has been linked to a
high incidence of ICC, including combined hepato-cholangiocel-
lular carcinoma (c-HCC-CC) (Tomimatsu et al, 1993; Shin et al,
1996; Su et al, 1996; Taguchi et al, 1996; Yamamoto et al, 1998).
Follow-up of patients with HCV infection therefore can detect
many cases of ICC as well as HCC. Although serum concentrations
of carcinoembryonic antigen (CEA) and carbohydrate antigen
(CA) 19-9 are commonly measured to detect and monitor of ICC,
insufficient sensitivity and specificity has been a problem with
using these established markers in this form of cancer (Kawarada
and Mizumoto, 1984, 1990; Wang et al, 1994; Yamanaka et al, 1995;
Nakamura et al, 1996; Chu et al, 1997; Kim et al, 1999). A more
accurate marker for ICC is needed.
In malignant epithelial cells, activated protease increases
degradation of cytokeratin; this results in release of large amounts
of cytokeratin fragments into the blood (Dohmoto et al, 2001; Wu
et al, 2002). The CYFRA 21-1 assay was developed to measure a
soluble fragment of cytokeratin 19 in serum. In non-small-cell lung
cancer, CYFRA 21-1 was found to be significantly more sensitive
than established markers, and this test may be a useful adjunct in
clinical monitoring during and following treatment (Pujol et al,
1993; Stieber et al, 1993; Sugama et al, 1994; van der Gaast et al,
1994; Takada et al, 1995; Lai et al, 1996; Brechot et al, 1997;
Nisman et al, 1998). In addition to lung cancer, CYFRA 21-1 has
been reported to be a useful marker for cervical carcinoma
(Gaarenstroom et al, 1995; Doweck et al, 2000), oesophageal cancer
(Brockmann et al, 2000; Kawaguchi et al, 2000), breast cancer
(Nakata et al, 2000), gastric cancer (Nakata et al, 1996), and
bladder cancer – (Sanchez-Carbayo et al, 1999). Little is known,
however, about the clinical significance of serum CYFRA 21-1 in
primary liver cancer, although Kashihara et al (1998) have
reported marked high concentration of serum CYFRA 21-1 in
four patients with severe advanced ICC. As cytokeratin 19 is
abundant in ICC (Osborn et al, 1986; Balaton et al, 1988; Johnson
et al, 1988; Moll et al, 1992), serum CYFRA 21-1 may be useful for
diagnosing and monitoring these neoplasms. In assessing relations
to histologic type and pathologic stage in primary liver cancer, we
compared serum CYFRA 21-1 with three widely used tumour
markers: AFP, CEA, and CA 19-9 in large number of patients with
primary liver cancer.
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Patients
The study was performed retrospectively using consecutively
obtained samples from 187 patients who underwent hepatic
resection for primary liver cancer. Serum samples were collected
just before surgery and were stored at  801C until analysis. All
patients were referred to the Department of Hepato-Biliary-
Pancreatic Surgery at Osaka City University Hospital between
1994 and December 2001, and had histologically confirmed
primary liver cancer. Their characteristics are listed in Table 1.
The patient population included 164 patients with HCC and 23
with ICC; of the latter, six had c-HCC-CC. Tumour stage was
defined according to the pathologic tumour-nodes-metastasis
(pTNM) classification proposed by the International Union
Against Cancer (Sobin and Wittekind, 1997).
Control blood samples were obtained from 87 patients with
nonmalignant liver diseases (Table 1). These patients
were diagnosed using clinical, radiologic, and laboratory criteria.
Diagnoses of cirrhosis were confirmed by liver biopsy specimen
examination. This study was conducted in accordance with
the Helsinki Declaration and the guidelines of the Ethics
Committee of our institution. Informed consent was obtained
from each patient.
Measurement of tumour markers
We measured CYFRA 21-1 using an electrochemiluminescent
immunoassay (ECLIA). The assay, using an Elecsys 2010 analyser
(Roche Diagnostics, Basel, Switzerland), is based on the ability of
an electrochemically luminescent molecule, a tris(2,20-bipyridyl)-
ruthenium (II) complex, to be repeatedly excited by tripropyla-
mine. The system can be applied to both competitive and
sandwich-format immunoassays. CYFRA 21-1 was recognised by
two mouse monoclonal antibodies, a biotinylated monoclonal
cytokeratin 19-specific antibody (Ks 19-1) and a monoclonal
cytokeratin 19-specific antibody (BM 19-21), directed against two
different epitopes of a fragment of cytokeratin 19. In the first
incubation, Ks 19-1 and BM 19-21 labelled with a ruthenium
complex were allowed to react, forming a sandwich complex. The
next incubation followed addition of streptavidin-coated micro-
particles, so the sandwich complex could bind to the particulate
solid phase via interaction of biotin and streptavidin. The reaction
mixture then was aspirated into the measuring cell, where the
microparticles were captured magnetically upon the surface of the
electrode. Unbound reactants were removed with a phosphate-
tripropylamine buffer. Application of voltage to the electrode then
induced chemiluminescent emission that was measured by a
photomultiplier.
For comparison, conventional tumour markers (CEA, CA 19-9,
and AFP) were measured by a chemiluminescent immunoassay
(CLIA).
Statistical analysis
Data are given as the median with 25th and 75th percentiles of
marker concentrations. Kruskal–Wallis one-way analysis of
variance was performed initially for multiple-comparison tests.
When this analysis was significant, pairs of groups were compared
using the Mann–Whitney U-test. To compare abilities of tumour
markers to distinguish patients with primary liver cancers from
those with benign liver disease, receiver operator characteristic
(ROC) curves, which correlate true- and false-positive rates
(sensitivity and (1 specificity)), were constructed using the
ROCKIT program (Metz et al, 1998a,b). In addition, areas under
the ROC curve (AUC) were calculated for each marker. The
statistical significance of differences between the two AUCs also
was determined.
RESULTS
CYFRA 21-1 distribution and histologic type of primary
liver cancer
Significant differences in CYFRA 21-1 concentration (median and
interquartile range) were noted between patients with primary
liver cancer (1.9; interquartile range 1.1–3.1ngml
 1) and those
with benign liver disease (1.4; 1.0–1.9; Mann–Whitney U-test,
P¼0.0009). Distributions of serum CYFRA 21-1 concentrations for
HCC (1.7; 1.1–2.7), ICC (5.0; 3.1–10.7), and benign liver disease
are shown in Figure 1. Significantly higher concentrations of
CYFRA 21-1 were noted in patients with ICC than in those with
benign liver disease (Mann–Whitney U-test, Po0.0001) or HCC
(Po0.0001).
Table 1 Characteristics of 187 patients with primary liver cancer and 87
controls with benign liver disease
Primary liver cancer
Median age, years (range) 63 (35–79)
Gender (male:female) 151:36
Histology
Hepatocellular carcinoma 164
Intrahepatic cholangiocarcinoma 23
Stage
I 28
II 92
III 36
IV 31
Benign liver disease
Median age, years (range) 60 (22–76)
Gender (male:female) 64:23
Histology
Chronic hepatitis C 63
Chronic hepatitis B 6
Liver cirrhosis 16
Haemangioma 2
Figure 1 Distribution of individual serum CYFRA 21-1 concentrations in
patients with primary liver cancer and benign liver diseases. Data are
presented as upper and lower quartile and range (box), median value
(horizontal line), and middle 90% distribution (whisker line).
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Table 2 shows the results for serum concentration and sensitivity
of AFP, CEA, CA 19-9, and CYFRA 21-1 in relation to histological
type. When cutoff values were selected according to 95%
specificity in the benign group, the cutoff values were 20.3ngml
 1
for AFP, 4.8ngml
 1 for CEA, 47.0Uml
 1 for CA 19-9, and
3.0ngml
 1 for CYFRA 21-1. AFP demonstrated a higher sensitivity
(59.1%) than other markers in patients with HCC. In patients with
ICC, the most sensitive marker was CYFRA 21-1 (87.0%). Although
CA 19-9 showed relatively high sensitivity in ICC patients (60.9%),
the sensitivity of CA 19-9 was 33.5% in HCC patients.
Analysis of ROC curves
Receiver operator characteristic curves were constructed to
compare the ability of the four markers to differentiate between
patients with malignant and benign liver disease. Curves for HCC
(Figure 2) and ICC (Figure 3) in distinction to benign liver disease
are illustrated. For patients with HCC, the AUC was 0.8170.03,
0.6170.04, 0.6470.03, and 0.5870.04 for AFP, CEA, CA 19-9, and
CYFRA 21-1, respectively. The AUC for AFP differed significantly
from that for other markers (Po0.0001). For patients with ICC, the
AUC was 0.5370.08, 0.8170.05, 0.8670.06, and 0.9570.03 for
AFP, CEA, CA 19-9, and CYFRA 21-1, respectively. A significant
difference was noted between the AUC for CYFRA 21-1 and those
for CEA (P¼0.0196) and AFP (Po0.0001); on the other hand, no
significant difference was noted between the AUC for CYFRA 21-1
and that for CA 19-9 (P¼0.0913). In the ICC group, ROC analysis
demonstrated that CYFRA 21-1 was superior to the other markers.
CYFRA 21-1 and pathologic variables in patients with ICC
For 23 patients with ICC, CYFRA 21-1 concentrations were
compared according to disease stage (Table 3, Figure 4). Median
and interquartile range of serum CYFRA 21-1 concentrations were
3.2 (3.1–3.8), 4.4 (3.1–7.6), and 11.5 (7.8–12.2) for stages I/II, III,
and IV, respectively. An overall tendency towards an increase in
serum concentration was observed from stages I/II to IV, and a
significant difference was noted (Kruskal–Wallis test, P¼0.0102).
No significant difference was evident for serum CEA or CA 19-9
concentration between tumour stages (Kruskal–Wallis test;
P¼0.0774 and 0.1252, respectively). The serum CYFRA 21-1
concentration also differed significantly according to the T factor
by the TNM classification (Table 3, Figure 4). Median and
interquartile ranges of serum CYFRA 21-1 concentrations were
3.1 (2.1–3.7), 4.4 (3.2–6.4), and 11.5 (7.8–12.2) for T1/2, T3, and
T4, respectively (Kruskal–Wallis test, P¼0.0038). Tumour size
and vascular invasion were related to serum CYFRA 21-1
concentration, while serum CYFRA 21-1 concentration did not
differ according to nodal status.
Table 2 Sensitivity of tumour markers in patients with primary liver cancer
CEA (ngml
 1) CA 19-9 (Uml
 1) AFP (ngml
 1) CYFRA21-1 (ngml
 1)
Benign liver disease
Median 1.8 (1.3–2.7) 16.0 (7.0–25.8) 6.5 (3.7–11.0) 1.4 (1.0–1.9)
Cutoff value 4.8 47.0 20.3 3.0
HCC
Median 2.8 (1.6–3.2) 23.0 (12.0–44.0) 38.5 (8.1–328.3) 1.7 (1.1–2.7)
Sensitivity 5.5% (9/164) 33.5% (55/164) 59.1% (97/164) 17.1% (28/164)
ICC
Median 3.2 (2.4–7.1) 96.0 (30.8–862.3) 6.3 (5.1–13.8) 5.0 (3.1–10.7)
Sensitivity 34.8% (8/23) 60.9% (14/23) 17.4% (4/23) 87.0% (20/23)
Data are given as the median with 25th and 75th percentiles of marker concentrations. Cutoff values selected according to 95% specificity in the benign group.
CEA¼carcinoembryonic antigen; fetoprotein¼AFP.
Figure 2 Receiver operating characteristic (ROC) curves in patients with
hepatocellular carcinoma and benign liver disease were constructed.
Figure 3 Receiver operating characteristic (ROC) curves in patients
with intrahepatic cholangiocarcinoma and benign liver disease were
constructed.
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ICC, including c-HCC-CC, has been reported to carry a poorer
postoperative prognosis than HCC reflecting more aggressive
invasion and frequent metastasis, especially to lymph nodes
(Maeda et al, 1995; Madariaga et al, 1998; Uenishi et al, 2000;
Inoue et al, 2000; Uenishi et al, 2001). Early diagnosis and curative
surgical resection therefore provide the only chance of long-term
survival for patients with ICC. Despite advances and refinements,
no tumour marker has shown satisfactory sensitivity or specificity
for early detection of ICC, for estimating extent of disease, or for
monitoring response to treatment. Thus, a reliable marker for ICC
would be a valuable addition to available diagnostic tests.
Cytokeratins are cytoskeletal intermediate filaments present in
almost all normal and malignant epithelial cells (Moll et al, 1992).
Characteristic combinations of cytokeratin polypeptides are
expressed in different epithelia depending on the organ and/or
type of differentiation (Osborn et al, 1986; Moll et al, 1992).
Epithelial cells in the liver also express characteristic cytokeratins.
In normal human liver, hepatocytes express cytokeratins 8 and 18,
while bile duct cells also contain cytokeratins 7 and 19 (Osborn
et al, 1986; Balaton et al, 1988; Johnson et al, 1988; Moll et al,
1992). Since this cytokeratin pattern ordinarily is preserved during
neoplastic transformation, ICC and the CC component of c-HCC-
CC contain cytokeratin 19, while HCC does not (Osborn et al, 1986;
Balaton et al, 1988; Johnson et al, 1988; Moll et al, 1992).
Therefore, a soluble fragment of cytokeratin 19, CYFRA 21-1, may
be a useful marker for ICC. Kashihara et al (1998) have reported
that high serum concentrations of CYFRA 21-1 in patients with
large liver cancer would suggest the existence of ICC rather than
HCC, since serum concentration of CYFRA 21-1 markedly elevated
in four patients with ICC, compared with that in 13 patients with
HCC. However, all the four patients had severe advanced and
unresectable tumours. We evaluated serum CYFRA 21-1 concen-
trations in 23 patients with various stage ICC to determine the
usefulness of CYFRA 21-1 as a marker for diagnosis of ICC, and
also to identify relation between CYFRA 21-1 levels and various
histological features including components of tumour staging
schema.
Tumour markers such as CA 19-9 and CEA can be used in
combination not only for diagnosis of gastrointestinal malignan-
cies but also for monitoring during and in follow-up treatment.
Some investigators have recommended that a possible diagnosis of
ICC should be considered when a hepatic tumour is associated
with high-serum CEA concentration, since serum CEA had
relatively high sensitivity in patients with ICC (Kawarada and
Mizumoto, 1984; Wang et al, 1994). Kubo et al (1995) reported that
a high-serum CEA concentration strongly suggests ICC in patients
with hepatolithiasis, even when no hepatic tumour is detected.
Generally, however, serum CEA concentrations are elevated in only
20–45% of patients with ICC (Yamanaka et al, 1995; Chu et al,
1997; Harrison et al, 1998; Kashihara et al, 1998; Kim et al, 1999;
Uenishi et al, 2001). In the present study, serum CEA also showed
a low sensitivity for ICC (34.8%). While serum CEA may be helpful
in diagnosis of some ICC and in follow-up of patients who showed
elevated titres prior to surgery, it is not sufficiently sensitive or
specific for reliable diagnosis of the disease (Kawarada and
Muzumoto, 1984; Wang et al, 1994). CA 19-9 currently is in wide
use, particularly for detecting bile duct cancer in patients with
primary sclerosing cholangitis (PSC) (Nichols et al, 1993; Ramage
et al, 1995; Bergquist et al, 1998; Chalasani et al, 2000). Serum CA
19-9 concentrations also are elevated in 65–80% of patients with
ICC, and CA 19-9 has been considered the most sensitive serologic
marker for diagnosis and follow-up of ICC (Kawarada and
Mizumoto, 1990; Yamanaka et al, 1995; Kim et al, 1999; Uenishi
et al, 2001). However, when we used a cutoff value giving a
specificity of 95% vs benign liver disease, CYFRA 21-1 had the
highest diagnostic sensitivity for ICC (87.0%). Importantly,
Table 3 Serum CYFRA 21-1 concentrations of 23 patients with
intrahepatic cholangiocarcinoma
Number Median (interquartile range) P-value
Tumour size (cm)
p4.0 12 3.2 (2.7–4.4) 0.0068
a
44.0 11 9.3 (5.0–11.6)
Vascular invasion
Present 13 8.4 (4.0–11.9) 0.0218
a
Absent 10 2.7 (3.1–5.1)
Number of tumour
Single 12 3.6 (3.1–5.1) 0.0648
a
Multiple 11 7.6 (3.5–12.0)
T factor
T1/2 7 3.1 (2.1–3.7) 0.0038
b
T3 9 4.4 (3.2–6.4)
T4 7 11.5 (7.8–12.2)
Lymph node metastasis
Present 6 6.9 (3.4–12.1) 0.3627
a
Absent 17 4.2 (3.1–9.6)
Stage
I/II 6 3.2 (3.1–3.8) 0.0102
b
III 10 4.4 (3.1–7.6)
IV 7 11.5 (7.8–12.2)
aMann–Whitney U-test,
bKruskal–Wallis test.
Figure 4 Distribution of individual serum CYFRA 21-1 values according
to stage (upper) and T factor (lower) in patients with intrahepatic
cholangiocarcinoma.
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(17.1%). Although the sensitivity of CA 19-9 was relatively high in
our patients with ICC (60.9%), its specificity for ICC was limited;
serum CA 19-9 was elevated in 33.5% of HCC patients. Serum
CYFRA 21-1 therefore may be a particularly useful marker for
distinguishing ICC from HCC in a radiologically demonstrated
hepatic tumour. However, our study could not clarify whether
screening for serum CYFRA 21-1 detects very early ICC, since only
two patients had a stage I tumour. Apparent sensitivity of a tumour
marker in a study is influenced by several factors, particularly
numbers of patients in early or advanced stages of cancer. Some
investigators have indicated that serum CYFRA 21-1 may be useful
for early detection of non-small-cell lung cancer, where CYFRA 21-
1 elevations were common even in patients with early stage disease
(Sugama et al, 1994; Takada et al, 1995). Prospective studies are
needed to assess the place of CYFRA 21-1 in screening for ICC.
When two or more tests are available for use in diagnosis,
comparison of ROC curves often will indicate which is best. The
diagnostic test with the ROC curve enclosing the largest area is
most accurate. For example, a high degree of specificity and
sensitivity of CYFRA 21-1 for diagnosis of non-small cell lung
cancer was shown by ROC curve findings (Pujol et al, 1993; Stieber
et al, 1993; Sugama et al, 1994; Takada et al, 1995; Nisman et al,
1998). Analysis of the AUCs clearly showed better discrimination
between ICC and benign liver diseases for CYFRA 21-1 than for
CEA or CA 19-9. These results indicated that serum CYFRA 21-1
should be a useful and reliable tumour marker for ICC.
Previous studies have validated CYFRA 21-1 as a marker for
monitoring disease in patients with various cancers, especially
since CYFRA 21-1 concentrations and the sensitivity of CYFRA 21-
1 increased progressively with clinical stage (Pujol et al, 1993;
Sugama et al, 1994; Gaarenstroom et al, 1995; Takada et al, 1995;
van der Gaast et al, 1995; Lai et al, 1996; Nakata et al, 1996; Brechot
et al, 1997; Nisman et al, 1998; Brockmann et al, 2000; Doweck
et al, 2000; Kawaguchi et al, 2000; Nakata et al, 2000) Our study
also demonstrated that serum CYFRA 21-1 concentration was
related to tumour stage of ICC, while serum CEA and CA 19-9
concentrations were not. CYFRA 21-1 concentrations differed
according to the tumour size and vascular invasion, but not
according to the number of tumours or nodal status. These results
suggested that CYFRA 21-1 should be useful for disease staging
and monitoring in patients with ICC.
In conclusion, serum CYFRA 21-1 should be a useful diagnostic
test for ICC given its outstanding sensitivity. Serum CYFRA 21-1
concentrations reflected differences in ICC tumour burden, so this
marker also could be applied to staging and monitoring.
Prospective studies should be performed to evaluate the real
impact of serum CYFRA 21-1 as a marker for ICC.
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